Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms.

Literature DB >> 24993879

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms.

Dennis Niebel¹, Jutta Kirfel¹, Viktor Janzen², Tobias Höller³, Michael Majores⁴, Ines Gütgemann¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2014 PMID： 24993879 DOI： 10.1182/blood-2014-04-569525

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

32 in total

Review 1. KDM1 class flavin-dependent protein lysine demethylases.

Authors: Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal: Biopolymers Date: 2015-07 Impact factor: 2.505

2. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.

Authors: Catherine L Carmichael; Jueqiong Wang; Thao Nguyen; Oluseyi Kolawole; Aissa Benyoucef; Charlotte De Mazière; Anna R Milne; Sona Samuel; Kevin Gillinder; Soroor Hediyeh-Zadeh; Anh N Q Vo; Yizhou Huang; Kathy Knezevic; William R L McInnes; Benjamin J Shields; Helen Mitchell; Matthew E Ritchie; Tim Lammens; Beatrice Lintermans; Pieter Van Vlierberghe; Nicholas C Wong; Katharina Haigh; Julie A I Thoms; Emma Toulmin; David J Curtis; Ethan P Oxley; Ross A Dickins; Dominik Beck; Andrew Perkins; Matthew P McCormack; Melissa J Davis; Geert Berx; Johannes Zuber; John E Pimanda; Benjamin T Kile; Steven Goossens; Jody J Haigh
Journal: Blood Date: 2020-08-20 Impact factor: 22.113

3. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.

Authors: Rossella Fioravanti; Annalisa Romanelli; Nicola Mautone; Elisabetta Di Bello; Annarita Rovere; Davide Corinti; Clemens Zwergel; Sergio Valente; Dante Rotili; Oronza A Botrugno; Paola Dessanti; Stefania Vultaggio; Paola Vianello; Anna Cappa; Claudia Binda; Andrea Mattevi; Saverio Minucci; Ciro Mercurio; Mario Varasi; Antonello Mai
Journal: ChemMedChem Date: 2020-02-14 Impact factor: 3.466

4. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.

Authors: N Sugino; M Kawahara; G Tatsumi; A Kanai; H Matsui; R Yamamoto; Y Nagai; S Fujii; Y Shimazu; M Hishizawa; T Inaba; A Andoh; T Suzuki; A Takaori-Kondo
Journal: Leukemia Date: 2017-02-17 Impact factor: 11.528

5. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα.

Authors: Kensaku Kohrogi; Shinjiro Hino; Akihisa Sakamoto; Kotaro Anan; Ryuta Takase; Hirotaka Araki; Yuko Hino; Kazutaka Araki; Tetsuya Sato; Kimitoshi Nakamura; Mitsuyoshi Nakao
Journal: Blood Adv Date: 2021-05-11

6. The transcriptional corepressor CBFA2T3 inhibits all-trans-retinoic acid-induced myeloid gene expression and differentiation in acute myeloid leukemia.

Authors: Nickolas Steinauer; Chun Guo; Jinsong Zhang
Journal: J Biol Chem Date: 2020-05-20 Impact factor: 5.157

7. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.

Authors: Monica Cusan; Sheng F Cai; Helai P Mohammad; Andrei Krivtsov; Alan Chramiec; Evangelia Loizou; Matthew D Witkin; Kimberly N Smitheman; Daniel G Tenen; Min Ye; Britta Will; Ulrich Steidl; Ryan G Kruger; Ross L Levine; Hugh Y Rienhoff; Richard P Koche; Scott A Armstrong
Journal: Blood Date: 2018-02-16 Impact factor: 22.113